The history of antibiotic resistance in Staphylococcus aureus spans more than half a century. Methicillin-resistant S. aureus (MRSA) has emerged as an almost ubiquitous pathogen in both the ...

The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole's revenues, currently a minor part of its CHF 131 million ($137 million ...

Meanwhile, the FDA has granted approval to a dozen new antibiotics that killed MRSA in a test tube but have not been better at saving patients’ lives (despite the companies’ and FDA’s ...

However, substantial differences in MRSA local epidemiology, infection control policy, antibiotic use pattern and patient mix make it difficult to compare results and draw solid conclusions.

The potential antibiotics were found to be able to kill MRSA in a lab dish and in mouse models with MRSA infection. In addition, the potential treatments were found to have very low toxicity ...

The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing market is projected to expand steadily over the next decade, rising from an estimated USD 4.3 billion in 2025 to USD 6.5 billion ...

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that has developed resistance to many antibiotics, making it a significant public health concern. MRSA infections can occur ...

Steve Schwarz underwent spinal surgery, only to later succumb to MRSA due to discontinuation of antibiotics at a care home. His family sued the doctors, resulting in a $1.65 million award.

The more antibiotics are used, the less effective they become. A bacterium called methicillin-resistant Staphylococcus aureus, known as MRSA, over time has built up resistance to front-line ...